Which patients have greatest need for elvitegravir/cobicistat/ emtricitabine/tenofovirDF-based therapy?
| Autor: | Claudio Viscoli, Lucia Taramasso, Antonio Di Biagio, Bianca Bruzzone, Giulia Gustinetti, Roberta Prinapori, Laura Sticchi |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2014 |
| Předmět: |
Special populations
Anti-HIV Agents Phosphorous Acids Resistance HIV Infections Quinolones Emtricitabine Deoxycytidine Elvitegravir Patents as Topic Cobicistat Side effects TenofovirDF Drug Discovery Antiretroviral treatment Humans Medicine Pharmacology (medical) business.industry Adenine General Medicine Virology Drug Combinations Thiazoles Integrase strand transfer inhibitor Infectious Diseases HIV-1 Carbamates business medicine.drug |
| Popis: | Elvitegravir/cobicistat/emtricitabine/tenofovirDF (EVG/COBI/FTC/TDF) is the new single-tablet, fixed-dose formulation containing an integrase strand transfer inhibitor recently approved as antiretroviral treatment. In this paper we analysed its use and advantages in naïve and experienced HIV-infected patients and we focused on special populations in which EVG/COBI/FTC/TDF could be a suitable option. Furthermore the manuscript reports the recent patent of EVG which may have an influence on the management of HIV-infected patients in the next future. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|